• proven international Project Manager in driving and managing team of experts around process developement, process transfert technology and Drug Development for the pharma and biotech industries. • visionary and results driven Leader with proven ability to quickly analyze key business drivers and develop and execute strategies that achieve Leadership positions and enhance bottom-line profits in the biotech and Pharmaceutical industries. • strong Leadership and interpersonal skills capable of resolving multiple and complex issues and motivating staff to top peak performance. • proven executive Leader with international experience in Change Management, Business Development, Finance, Operations, and Research within biotech and Pharmaceutical industries.
Chief Operations Officer (acting)
Since June 2017
biofilm pharma develops the next generation of antibiotics with a key and unique anti-biofilm added-value anti-biofilms are first-in-class drugs able to prevent the dormancy or hibernation of Bacteria, forming the so-called biofilms, linked to the development of resistances we use a highly proven technology licensed from biofilm control, standardized (iso13485), automated, daily running, which brings worldwide unique screening capacity for anti-biofilm drugs. this breakthrough technology is already in Clinical Validation for Diagnostic tests hitting the market in 2018 anti-biofilms are for high risk infections. our first focus: the diabetic foot ulcer infections, when there is a risk of amputation for patients with a chronic disease and long-term Treatment biofilm pharma is driven by an experimented team connected to a rich network of worldwide renowned key opinion leaders these first-in-class antibacterials for first-line treatments are not competing with old antibiotics. they are driving to a peak Sales above $1 billion in 2028 ! Biofilm Pharma develops the next generation of antibiotics with a key and unique anti-biofilm added-value Anti-biofilms are first-in-class drugs able to prevent the dormancy or hibernation of bacteria, forming the so-called biofilms, linked to the development of resistances We use a highly proven technology licensed from BioFilm Control, standardized (ISO13485), automated, daily running, which brings worldwide unique screening capacity for anti-biofilm drugs. This breakthrough technology is already in clinical validation for Diagnostic tests hitting the market in 2018 Anti-biofilms are for high risk infections. Our first focus: the Diabetic Foot Ulcer Infections, when there is a risk of amputation for patients with a chronic disease and long-term treatment BioFilm Pharma is driven by an experimented team connected to a rich network of worldwide renowned Key Opinion Leaders These first-in-class antibacterials for first-line treatments are not competing with old antibiotics. They are driving to a peak sales above $1 Billion in 2028 !
Chief Operating Officer (acting)
Since January 2016
acticor biotech is a spin-off company from inserm (French national institute of Health and Medical Research) founded in november 2013 and located in the inserm u1148 buildings inside the bichat Hospital in paris. acticor biotech develops a drug candidate based on academic research on therapeutic Monoclonal Antibodies conducted by its founders. this biodrug will aim at reducing death, disabilities and recurrence of ischemic stroke. excellent efficacy and innocuity (no bleedings) have been demonstrated on the most pertinent Animal models, resulting in a very favorable risk/benefit ratio. acticor biotech is presently close to phase 1 which will start in early q4 2017. Acticor Biotech is a spin-off company from Inserm (French National Institute of Health and Medical Research) founded in November 2013 and located in the Inserm U1148 buildings inside the Bichat Hospital in Paris. Acticor Biotech develops a drug candidate based on academic research on therapeutic monoclonal antibodies conducted by its founders. This biodrug will aim at reducing death, disabilities and recurrence of ischemic stroke. Excellent efficacy and innocuity (no bleedings) have been demonstrated on the most pertinent animal models, resulting in a very favorable risk/benefit ratio. Acticor Biotech is presently close to phase 1 which will start in early Q4 2017.
Director Process Engineering (acting)
Since April 2015
bio-Sourcing is an Animal Health company focus on biologicals. with its unique production platform, bio-Sourcing is able to provide the industry with an affordable production process that is both flexible and environmentally safe according to Sustainable development standards. Bio-Sourcing is an Animal Health company focus on biologicals. With its unique production platform, Bio-Sourcing is able to provide the industry with an affordable production process that is both flexible and environmentally safe according to sustainable development standards.
Founder/ Consultant in Drug Development and Business Strategy
Since January 2014
we provide solutions customized to the life science industry. 3biotech vision is defined by the desire to accelerate the development, industrialization and Commercialization of products and services in the phama, biotech and medtech industries. we focus on helping investors/ leaders/ companies in converting Laboratory concepts or visions into well defined projects and end products. more information at http://www.3biotech.com We provide solutions customized to the life science industry. 3Biotech vision is defined by the desire to accelerate the development, industrialization and commercialization of products and services in the Phama, Biotech and Medtech industries. We focus on helping Investors/ leaders/ companies in converting laboratory concepts or visions into well defined projects and end products. More information at http://www.3biotech.com
European Executive Director of Bio/Pharmaceutical SolutionsSeptember 2011 --- October 2013
established covance biopharm cmc as the european market Leader in integrated Drug Development services business responsabilitiy and coordination between 3 european sites: 2 in uk and 1 in france. proactively evaluated competitive activity and business Operations and restructured the organization - generated a 10% of revenue growth in europe within a year. - exceeded annual profit margin target per more than 10% since 2011.
General Manager of Covance Laboratory SASJanuary 2011 --- October 2013
led the company in a turnaround that took it from a cost center (R&D sanofi site) to a profit center (CRO) in a very sharp deadline. identified potential people-side risks and anticipated points of resistance and developed specific plans to mitigate or address concerns. created a client centric 'can-do' attitude. increased annual Sales revenue by 8m€ within 2 years (20% increase). exceeded annual profit margin by 1.2 m€ each year (11%). net promoter score (nps®) close to 72% (60% higher than target) 3 reorganizations approved by work council and unions.
Mission (3Biotech): Management of Business developmentOctober 2010 --- April 2011
assignement: lead the company in a turnaround that will take it from a technology platform to a Vaccines and therapeutic Peptides producer. identify opportunities for new revenue. developed a 2-years Strategy and plan supporting an annual revenue growth of 1 m€ and the development of 3 products in Preclinical phase. prospect decision centers and establish contacts at the highest level. coordinate Research and Business Development teams, to best position our value proposition. identify and negotiate strategic partnerships
Consultant/ FounderJanuary 2010 --- April 2011
we provide solutions customized to the biotech industry (white, red and green). we focus on helping leaders/companies in converting Laboratory concepts or visions into well defined projects and end products. services: Executive Management, governance, Business Development, strategic partnerships, Product Development Planning, organisational development, recruitment Strategy. biotech Process development : design, operation, optimization, selection of suppliers, equipements and facilities. project execution plans Project Management
General Manager of NNE Pharmaplan FranceJune 2005 --- June 2010
led the company in a turnaround that took it from an unknown player position to become one of the leaders in its market. developed a 3-year Strategy and plan supporting an annual turnover growth of 2 m€. led executive, operational and financial direction with full p&l responsibility. reported to the group CEO. • increased turnover from 2m€ to 7.8m€ in 3 years by increasing market share and establishing strategic alliances. • captured exceptional market shares with more than 30 key players in the pharma and biotech industry like sanofi-aventis, gsk biologics, ipsen, virbac… • acquired and financially turnaround one of our competitors, then merged. • open a new office in lyon to facilitate recruitment and increase our market share. • implemented and received ISO 9001 certification with a Customer Satisfaction higher than 94%
Head of development/ IndustrialisationOctober 2000 --- May 2005
brought on board to transform Laboratory concepts to industrial commercialized products and to prepare an ipo. • designed and implemented a platform for development and production of therapeutics and industrial Proteins: 90 m2 with a total investment cost of 400k€. • hired, trained, evaluated, and discharged staff, and resolved personnel grievances. • set-up and monitored product standards, examining samples of raw products or directing Testing during processing, to ensure finished products are of prescribed quality according to GMP standards. • reviewed Operations and confered with technical or administrative staff to resolve production or processing problems. • reviewed plans with Research and support staff to develop new products and processes. • successfully industrialized more than 10 products for key players like degussa, adisseo, henkel… • ipo has been postponed due to the events of the 11th of september
Senior Project ManagerSeptember 1995 --- October 2000
discovered and industrialized an innovative biochemical route to a key feed ingredient. key activities entail development and management of budget, Training, interfacing with staff and client during project cycle, contract negotiations, product european approval, and meeting project milestones and delivery dates. manage an international and multidisciplinary team of 15 persons and control budget of up to 1.5 m€. • saved 10% on production costs and reduction of over 80% of solid waste • recipient of the rhône-poulenc Research award.
Chemical EngineerSeptember 1992 --- September 1995
R&D engineer in biocatalysis
PhD studentJanuary 1988 --- January 1992
biosynthesis in two-liquid phase environment (aqueaous/ organic phases)
AdaptabilityCreative thinkingCuriosityDiligenceEfficiencyKindnessCritical thinkingFlexibilityOptimismProactivityResult OrientedStrategic thinkingTrust
Biochemistry R&D Phase I Lab scale batchescGMPCMCCMC CMC Regulatory AffairsDrug development processDrug DevelopmentDue DiligenceGMPMicrosoft ProjectNew Business DevelopmentPhase IPhase IIPreclinical developmentPreclinical ResearchPreclinical SafetyPresentation SkillsProblem SolvingProject Management
MBA in Finance and accounting Executive MBA administration Program from SIMI in 2007
Ph.D. in Biotechnology from University of Groningen in 1992
Ingeneer in Chemistry from Ecole Nationale Supérieure de Chimie de Montpellier in 1988
Training and Certification
PH D in 1992 Certification